BIONEXUS GENE LAB CORP (BGLC) Stock Income Statement
NASDAQ:BGLC - Nasdaq - US0906283066 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.51M | 9.77M | 10.93M | 13.36M | 11.39M | |||
| Cost Of Goods | 8.22M | 8.44M | 9.67M | 11.10M | 9.67M | |||
| Gross Profit | 1.29M | 1.33M | 1.26M | 2.27M | 1.72M | |||
| Operating Expenses | 2.97M | 3.92M | 1.55M | 1.21M | 450.00K | |||
| Research and Development | 47.50K | 55.00K | N/A | N/A | N/A | |||
| Selling, General, and Administrative Expenses | 3.20M | 4.35M | 1.73M | 1.28M | 1.33M | |||
| Operating Income | -1.68M | -2.59M | -290.00K | 1.05M | 1.27M | |||
| Interest Income/Expense | 86.70K | -13.90K | -10.00K | -10.00K | -10.00K | |||
| Income Before Taxes | -1.59M | -2.61M | -300.00K | 1.04M | 1.26M | |||
| Income Tax | 3.50K | 21.50K | 50.00K | 290.00K | 170.00K | |||
| Net Income | -1.60M | -2.63M | -360.00K | 750.00K | 1.09M | |||
| EBITDA | -1.58M | -2.51M | -200.00K | 1.14M | 1.36M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.90 | -1.66 | -0.24 | 0.52 | 1.27 | |||
| Statistics | ||||||||
| Gross Profit Margin | 13.56% | 13.61% | 11.53% | 16.99% | 15.10% | |||
| Profit Margin | -16.81% | -26.91% | -3.29% | 5.61% | 9.57% | |||
| Operating Profit Margin | -17.68% | -26.54% | -2.65% | 7.86% | 11.15% | |||
All data in USD